NIDA Grant Opportunity to Test Approaches to Opioid Use Disorder Treatment That Use 21st Century Cures Act Funding Awarded to States – Applications Due June 20, 2017

The Department of Health and Human Services has announced it will soon provide $485 million in grants to help states and territories combat the opioid crisis. The funding, which is the first of two rounds provided for in the 21st Century Cures Act, will be provided through State Targeted Response to the Opioid Crisis Grants administered by the Substance Abuse and Mental Health Services Administration (SAMHSA).

Taking advantage of this opportunity, the National Institute on Drug Abuse (NIDA) recently announced an innovative new funding opportunity to test approaches to expand pharmacological treatment of opioid use disorders (OUDs). NIDA intends to commit $2,000,000 in FY 2018 to fund 3-4 awards to test approaches undertaken by states using funds authorized under the 21st Century Cures Act, either in the general health care sector or by improving treatment linkage for individuals with OUDs who receive naloxone for the reversal of overdose.

Importantly, projects responding to this announcement must leverage opportunities made available by funding that states received from SAMHSA and they must include relevant state agency staff as key personnel. Applications proposing to test non-medical treatments for OUD are not responsive. The proposed project must focus on the following outcomes: drug use and/or overdose deaths; length of time on medication, treatment retention, time to relapse; and at least one other physical or mental health related outcome. Researchers interested in including health economic or quality of life measures related to these outcomes in their application can contact the CHERISH Consultation Service for assistance.

Possible research topics include but are not limited to OUD medications provided in emergency departments, pharmacies, and inpatient unities, telehealth approaches for providing OUD medications, models of care that provide a choice of OUD medications to patients, naloxone delivery models and continuity of care models such as the Hub and Spoke Model or the ECHO model.

There is a relatively short time frame for submitting these applications, which are due on June 20, 2017. Letters of intent should be submitted 30 days before the application deadline (May 22, 2017). For more details, please refer to the funding announcement (RFA-DA-18-005 ).